Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Assiut University
Modality
UNKNOWN
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06337994CT.gov Memantine Hydrochloride for Treatment of Cognitive Dysfunction Due to Traumatic Brain Injury | — | Completed | — | — | — |
NCT05531383CT.gov Effect of Early Memantine Administration on Outcome of Patients With Moderate to Severe Traumatic Brain Injury | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Traumatic Brain Injury
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Memantine Hydrochloride (this asset) | Assiut University | P3 | B · 57 |
| Melatonin | Children's National Research Institute | P4 | BBB |
| Apsolol | Tanta University | P4 | BBB |
| Nepenthe | Henry M. Jackson Foundation for the Advancement of Military Medicine | P4 | BB |
| Amantadine | SHINKEI Therapeutics, Inc | P4 | BB |
| Dexmedetomidine | Universitas Jenderal Soedirman | P4 | BB |
| Lacto-Flavin | POLYSAN Scientific & Technological Pharmaceutical Company | P3 | BB |
| Serostim | Anhui Provincial Hospital | P4 | BB |
| Fentanyl | Henry M. Jackson Foundation for the Advancement of Military Medicine | P4 | BB |
+42 more in the Traumatic Brain Injury cohort
Other indications for Memantine Hydrochloride
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Alzheimer Disease | — | P4 | BB · 67 |
| Frontotemporal Dementia | — | P3 | B · 62 |
| Metastatic Malignant Neoplasm In The Brain | — | P3 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Memantine Hydrochloride in Traumatic Brain Injury. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/memantine-hydrochloride-traumatic-brain-injury
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →